Early-phase study to assess inhibitor ribociclib in patients with recurrent glioblastoma or anaplastic glioma
NCT02345824
In this study, patients with recurrent glioblastoma or anaplastic glioma were treated with ribociclib for 8-14 days before surgical resection of tumor to assess tumor pharmacokinetics and biomarker changes. Patients with Rb+ tumors continued ribociclib treatment until disease recurrence/progression.

Reference manuscript

Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma.
Todd W Miller, Nicole A Traphagen, Jing Li, Lionel D Lewis, Beatriz Lopes, Ashok Asthagiri, Johanna Loomba, Jenny De Jong, David Schiff, Sohil H Patel, Benjamin W Purow, Camilo E Fadul.
J Neurooncol. 2019 Sep;144(3):563-572. doi: 10.1007/s11060-019-03258-0. Epub 2019 Aug 9.